Pliant Therapeutics, Inc. (PLRX) stock
PLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.70−0.04 (-5.81%)
Close on Nov 13, 2026Market cap $43.16MP/E –Yield 0.00%
Pliant Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Pliant Therapeutics's total assets was $169.88M at Sep 30, 2026. For fiscal 2025 it was $225.23M, down 43.3% from the year before. The highest annual figure on record is $512.15M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $225.23M | -43.3% |
| FY2024 | Dec 31, 2024 | $396.95M | -22.5% |
| FY2023 | Dec 31, 2023 | $512.15M | +46.1% |
| FY2022 | Dec 31, 2022 | $350.61M | +58.5% |
| FY2021 | Dec 31, 2021 | $221.22M | -25.1% |
| FY2020 | Dec 31, 2020 | $295.53M | +148.2% |
| FY2019 | Dec 31, 2019 | $119.06M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $169.88M | -38.6% |
| Q2 FY2026 | Jun 30, 2026 | $189.88M | -36.7% |
| Q1 FY2026 | Mar 31, 2026 | $202.60M | -41.2% |
| Q4 FY2025 | Dec 31, 2025 | $225.23M | -43.3% |
| Q3 FY2025 | Sep 30, 2025 | $276.60M | -37.9% |
| Q2 FY2025 | Jun 30, 2025 | $299.82M | -38.0% |
| Q1 FY2025 | Mar 31, 2025 | $344.77M | -33.9% |
| Q4 FY2024 | Dec 31, 2024 | $396.95M | -22.5% |
| Q3 FY2024 | Sep 30, 2024 | $445.67M | -17.5% |
| Q2 FY2024 | Jun 30, 2024 | $483.73M | -15.9% |
| Q1 FY2024 | Mar 31, 2024 | $521.61M | -12.8% |
| Q4 FY2023 | Dec 31, 2023 | $512.15M | +46.1% |
| Q3 FY2023 | Sep 30, 2023 | $540.46M | +43.3% |
| Q2 FY2023 | Jun 30, 2023 | $574.89M | +211.4% |
| Q1 FY2023 | Mar 31, 2023 | $597.88M | +203.5% |
| Q4 FY2022 | Dec 31, 2022 | $350.61M | +58.5% |
| Q3 FY2022 | Sep 30, 2022 | $377.18M | +61.1% |
| Q2 FY2022 | Jun 30, 2022 | $184.62M | -27.8% |
| Q1 FY2022 | Mar 31, 2022 | $197.02M | -28.4% |
| Q4 FY2021 | Dec 31, 2021 | $221.22M | -25.1% |
| Q3 FY2021 | Sep 30, 2021 | $234.12M | -25.0% |
| Q2 FY2021 | Jun 30, 2021 | $255.72M | -22.2% |
| Q1 FY2021 | Mar 31, 2021 | $275.25M | +131.2% |
| Q4 FY2020 | Dec 31, 2020 | $295.53M | – |
| Q3 FY2020 | Sep 30, 2020 | $312.32M | – |
| Q2 FY2020 | Jun 30, 2020 | $328.80M | – |
| Q4 FY2019 | Dec 31, 2019 | $119.06M | – |
See a number that looks wrong?